Pathophysiological Mechanisms Involved in the Pronostic and Evolution of Non-Small Cell Lung Cancer (NSCLC) at All Stages of the Disease

Sponsor
University Hospital, Bordeaux
Study ID
NCT07470476
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Translational analyses — BIOLOGICAL
    Translational analyses of clinical data and biological samples

Study Details

This single-center observational cohort study conducted at Bordeaux University Hospital aims to establish a structured clinico-biological platform in non-small cell lung cancer (NSCLC) to investigate the biological mechanisms involved in tumor initiation, progression, and relapse across all disease stages (I-IV). A total of 150 consecutive adult patients with histologically or cytologically confirmed NSCLC will be included over a 3-year period. Tumor samples will undergo translational analyses. These biological data will be correlated with pseudonymized clinical data collected from medical records and the institutional clinical data warehouse. The primary objective is to characterize the molecular, metabolic, and immune mechanisms associated with tumor progression and recurrence in NSCLC. The central hypothesis is that integrating comprehensive clinical data with in-depth molecular and immunological analyses of tumor tissues will identify biologically distinct patterns associated with disease evolution, therapeutic resistance, and prognosis. Such integrated clinico-biological signatures may improve patient stratification and contribute to the identification of novel biomarkers and therapeutic targets in NSCLC.

Key Dates

First listed
Mar 13, 2026
Start date
Jun 30, 2026
Status verified
Apr 2026
Primary completion
Jun 30, 2036
Completion
Jun 30, 2041

Study Design

Enrollment
150 participants (estimated)

Arms

  • Arm: Localised NSCLC treated by surgery +/- adjuvant therapy
  • Arm: Localised NSCLC treated by neoadjuvant therapy followed by surgery
  • Arm: Locally advanced NSCLC unaccessible to a surgery
  • Arm: Metastatic NSCLC without oncogenic addiction
  • Arm: Metastatic NSCLC with oncogenic addiction

Primary Outcome Measure

Molecular, metabolic, and immune mechanisms associated with tumor progression and relapse in NSCLC [ Time Frame: From diagnosis until death or study discontinuation, with a maximum follow-up of 10 years ]

Central Contacts

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies